Abstract
PurposeThe purpose of this study was to determine the prognostic role of ten eleven translocation (TET) family proteins and DNA glycosylase (TDG) in patients with early breast cancer (EBC).MethodsExpression of mRNAs encoding TET1–3 and TDG in 162 breast cancer tissues was quantified using real-time polymerase chain reaction analysis. The general characteristics of patients and clinicopathologic factors were collected. Estimation of patient survival was calculated using the Kaplan–Meier method, and independent prognostic indicators were analyzed using Cox regression analysis.ResultsThe level of TET1 mRNA was significantly related to overall survival (OS) (P = 0.022). Multivariate analysis shows that the TNM stage was an independent predictor of disease-free survival (DFS) (HR = 1.761, 95% CI: 1.124–2.761, P = 0.014) and OS (HR = 2.135, 95% CI: 1.070–4.263, P = 0.032). Further, in patients with EBC who were treated with anthracyclines, Kaplan–Meier analysis indicates that the levels of TET3 and TDG mRNAs were related to DFS (P = 0.026 and 0.030, respectively), and multivariate analysis reveals that high levels of TET3 (HR = 1.944, 95% CI: 1.029–3.672, P = 0.040) and TDG (HR = 2.178, 95% CI: 1.140–4.163, P = 0.018) mRNAs were independent indicators of favorable DFS.ConclusionsOur study indicates that EBC patients with decreased expression of TET1 mRNA had worse OS and that the levels of TET3 and TDG mRNAs were independent prognostic factors for patients who received anthracycline chemotherapy.
Highlights
Breast cancer is one of the most commonly diagnosed cancers in women, with an estimated 1.2 million new cases worldwide each year, and represents approximately 25% of cancers of women [1, 2]
The level of TET1 mRNA was significantly related to overall survival (OS) (P = 0.022)
Multivariate analysis shows that the TNM stage was an independent predictor of disease-free survival (DFS) (HR = 1.761, 95% CI: 1.124–2.761, P = 0.014) and OS (HR = 2.135, 95% CI: 1.070–4.263, P = 0.032)
Summary
Breast cancer is one of the most commonly diagnosed cancers in women, with an estimated 1.2 million new cases worldwide each year, and represents approximately 25% of cancers of women [1, 2]. Patients respond well to treatment, and standard guideline has been promoted in our country in recent years; breast cancer remains the second most frequent cause of cancer-related deaths, and 1.2 million people die each year in our country [3, 4]. The development of new techniques to predict the prognosis of breast cancer is crucial for administering more timely and appropriate treatment, and further research is required to identify novel molecular markers of prognosis. Further, dysregulated DNA methylation of tumor suppressor genes occurs in different types of cancer [12]. Marc Milstein[13] reported that RIN1 gene was silenced in breast tumor cell lines compared to cultured human mammary epithelial cells and DNA methylation within the RIN1 promoter contributed to silence of the gene
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
